Healthcare system engagement and algorithm-identified cancer incidence following initiation of a new medication.

Monica E D'Arcy Til StürmerRobert S SandlerJohn A BaronMichele L Jonsson-FunkMelissa A TroesterJennifer L Lund

Published in: Pharmacoepidemiology and drug safety (2022)

Lower HU before-and increased HU around AHT initiation-seem to drive excess short-term aiCRC incidence. Person-time and case accrual should only begin when incidence stabilizes. When comparison groups within a study differ by HU, outcome-detection bias may exist. Similar observations may exist in other settings when typical HU is delayed (e.g., cancer screening during SARS-CoV-2).

Keyphrases

papillary thyroid
sars cov
risk factors
squamous cell
healthcare
machine learning
deep learning
lymph node metastasis
emergency department
childhood cancer
adverse drug
electronic health record
quantum dots